VIOLIN Logo
Cov19VaxKB Banner
Search: for Help
Home
Introduction
Statistics
Authorized Vaccines
Phase III Vaccines
Phase II Vaccines
Phase I Vaccines
Preclinical Vaccines
Vaccine Safety
Vaccine Design
News
Data Submission
Data Exchange
Data Download
Links
Documentation
Updates
Acknowledgements
FAQs
Disclaimer
Contact Us
UMMS Logo

Authorized COVID-19 Vaccines

This site collects existing COVID-19 vaccines that are authorized or authorized for public use in at least one country as of January 8, 2021. This list includes vaccines that have received Emergency Use Authorization by a regulatory agency.

Existing vaccines that are authorized for public use include:

  1. AZD1222
    • Other names: ChAdOx1 nCoV19, Covishield
    • Manufacturer: AstraZeneca, University of Oxford
    • Countries where authorized: UK, India, Argentina
    • Clinical trial ID:
      • Phase III: NCT04516746 (protocol)
        • Age subgroups: 18-64 years, 65 years and above
        • Location: USA, Argentina, Chile, Colombia, Peru
      • Phase III: NCT04540393
        • Age subgroups: 18 years and above
        • Location: Russia
      • Phase III: NCT04536051
        • Age subgroups: 18-55 years, 56-69 years, 70 years and above
        • Location: Brazil
      • Phase III: ISRCTN89951424
        • Age subgroups: 18-55 years
        • Location: Brazil
      • Phase III: CTRI/2020/08/027170
        • Age subgroups: 18 years and above
        • Location: India
    • Type: Recombinant vector vaccine
    • Publications:
      • Barrett et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2020; ; . [PubMed: 33335322].
      • Ewer et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; ; . [PubMed: 33335323].
      • Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; S0140-6736(20)32661-1. [PubMed: 33306989].
      • Folegatti et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249); 467-478. [PubMed: 32702298].
    • VIOLIN: 5774
    • VO: VO_0005158
  2. BBIBP-CorV
    • Manufacturer: Beijing Institute of Biological Products, Sinopharm
    • Countries where authorized: China, Bahrain, United Arab Emirates
    • Clinical trial ID:
      • Phase III: NCT04560881
        • Age subgroups: 18-85 years
        • Location: Argentina
      • Phase III: NCT04510207
        • Age subgroups: 18 years and above
        • Location: Bahrain, Egypt, Jordan, UAE
      • Phase III: ChiCTR2000034780
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: UAE
    • Type: Inactivated or “killed” vaccine
    • Publications:
      • Wang et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3); 713-721. [PubMed: 32778225].
    • VIOLIN: 5776
    • VO: VO_0005166
  3. BNT162b2
    • Other names: Comirnaty, Tozinameran
    • Manufacturer: BioNTech, Pfizer
    • Countries where authorized: USA, Canada, and other countries
    • Clinical trial ID:
      • Phase I/II/III: NCT04368728 (protocol)
        • Age subgroups:
          • Phase I: 18-55 years, 65-85 years
          • Phase II/III: 12-15 years, 16-55 years, 56 years and above
        • Location: USA, Argentina, Brazil, Germany, South Africa, Turkey
    • Type: mRNA vaccine
    • Publications:
      • Polack et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27); 2603-2615. [PubMed: 33301246].
      • Walsh et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; ; . [PubMed: 33053279].
      • Sahin et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020; ; . [PubMed: 32998157].
      • Mulligan et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; ; . [PubMed: 32785213].
    • Additional links:
    • VIOLIN: 5784
    • VO: VO_0004987
  4. COVAXIN
    • Other names: BBV152
    • Manufacturer: Bharat Biotech
    • Countries where authorized: India
    • Clinical trial ID:
    • Type: Inactivated or “killed” vaccine
    • VIOLIN: 5795
    • VO: VO_0004991
  5. Gam-COVID-Vac
    • Other names: Sputnik V
    • Manufacturer: Gamaleya Research Institute
    • Countries where authorized: Russia
    • Clinical trial ID:
      • Phase III: NCT04530396
        • Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 61 years and above
        • Location: Russia
      • Phase III: NCT04564716
        • Age subgroups: 18-60 years
        • Location: Belarus
      • Phase III: NCT04642339
        • Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
        • Location: Venezuela
      • Phase III: NCT04656613
        • Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
    • Type: Recombinant vector vaccine
    • Publications:
      • Logunov et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255); 887-897. [PubMed: 32896291].
    • VIOLIN: 5777
    • VO: VO_0005163
  6. mRNA-1273
    • Manufacturer: Moderna
    • Countries where authorized: USA, Canada, UK
    • Clinical trial ID:
      • Phase III: NCT04470427 (protocol)
        • Age subgroups: 18-64 years, 65 years and above
        • Location: USA
        • Race/ethnicity:
          • Asian: 4%
          • Black/African American: 10%
          • Hispanic/Latinx: 20%
          • White: 63%
          • All others: 3%
    • Type: mRNA vaccine
    • Publications:
      • Baden et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; ; . [PubMed: 33378609].
      • Anderson et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; ; . [PubMed: 32991794].
    • Additional links:
    • VIOLIN: 5789
    • VO: VO_0005157

Provenance: All data in Cov19VaxKB originates from manual curation of reliable resources.

Note: The page was updated on January 8, 2021. We plan to update this page on a weekly or even a daily basis. Please provide us with any new information that you believe would be useful if included on the website.